Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyRegional therapyVisceral SurgeryDiseaseBreast CancerColon CancerFallopian Tube CarcinomaGastric CancerOvarian TumorPeritoneal Carcinomatosis, SecondarySubgroupBRCA mutationEpCAM positiveserous, borderlineserous, low-gradeICD10C16.-C16.0C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C50.-C56C57.0C78.6MeSHCarcinoma, Ovarian EpithelialColorectal NeoplasmsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsStomach NeoplasmsSequenceChemotherapyChemo-substanceBevacizumabBinimetinibCatumaxomabCisplatinCyclophosphamideFluorouracilMitomycinNab-paclitaxelNaCl 0.9%NiraparibOlaparibPembrolizumabRelacorilantChemo-substanceBevacizumabBinimetinibCatumaxomabCisplatinCyclophosphamideFluorouracilMitomycinNab-paclitaxelNaCl 0.9%NiraparibOlaparibPembrolizumabRelacorilantChemo-substanceBevacizumabBinimetinibCatumaxomabCisplatinCyclophosphamideFluorouracilMitomycinNab-paclitaxelNaCl 0.9%NiraparibOlaparibPembrolizumabRelacorilantChemo-substanceBevacizumabBinimetinibCatumaxomabCisplatinCyclophosphamideFluorouracilMitomycinNab-paclitaxelNaCl 0.9%NiraparibOlaparibPembrolizumabRelacorilantNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateNo. Substances235Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseintraoperativMaintenanceTherapy intentionpalliativeRisksAlopeciaAnemia Hb below 8g/dlBleedingCardiotoxicityConstipationDiarrheaDyspneaEdemaElectrolyte DisturbanceEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFistulasGastrointestinal ToxicityHeadacheHypertensionHypomagnesemiaIncrease AminotransferasesIncrease Creatinine PhosphokinaseInfectionsLymphopeniaNeutropeniaPainProteinuriaPyrexiaRashThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorGhanipour LGrisham RNHeiss MMKuijpers ALorusso DMirza MMoore K / Pujade-Lauraine ETillmanns Tvan Driel WZsiros RDiseaseNeudiagnostiziertes Ovarial-Ca, Eileiter-Ca oder Peritoneal-Ca, Stadium III mit neoadjuvanter Therapie, ECOG 0-2Ovarial-Ca, Rezidiv, platinsensitiv, Zweitlinie, BRCA Mutation, ECOG 0-1Ovarial-Ca/Peritoneal-Ca, platinresistent, 1-3 VortherapienOvarialkarzinom, serös, low-grade oder Borderline-Tumor, Progress nach platinhaltiger ChemotherapiePeritonealkarzinom durch kolorektales Ca oder Pseudomyxoma peritonii, operabel, T1-T4, Stadium I-IVPeritonealkarzinose, sekundärPeritonealkarzinose, sekundär, EpCAM positiv in malignen Zellen in Aszitesrezidivierendes Ovarialkarzinom, fallopian tube or primary peritoneal cancer, ECOG 0-1rezidiviertes Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom, Cisplatin-sensitiv, Drittlinie, ECOG 0-1wiederkehrendes oder fortschreitendes Ovarial-Ca/Peritoneal-Ca, Stadium I-IV, nach Platintherapie, ECOG 0-1OriginCologne-Merheim Medical Center, University of Witten-Herdecke, Cologne, GermanyDepartment of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkDepartment of Gynecology, Netherlands Cancer Institute, AmsterdamDepartment of Oncology, Rigshospitalet–Copenhagen University Hospital, ENGOT-OV16/NOVA InvestigatorsDepartment of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, AmsterdamHumanitas University, Pieve Emanuele, Italy; Humanitas San Pio X Hospital, Milan, Italy, ROSELLA TrialMemorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, 3 MILO/ENGOT-ov11 StudyStevenson Cancer Center, University of Oklahoma, SOLO2/ENGOT-Ov21 investigatorsThe West Clinic, Memphis, USAUppsala University, Uppsala, SwedenProtokolle in Überarbeitung 10 protocols foundBinimetinib 45, Ovarian Ca (PID2671 V1.0)Catumaxomab (10/20/50/150), Peritoneal Carcinomatosis, Secondary (PID3037 V1.0)EPIC - Fluorouracil 400, Peritoneal Carcinomatosis, Secondary (PID2709 V1.0)HIPEC - Cisplatin 100, Ovarian ca (PID108 V2.1)HIPEC - Mitomycin 35, Peritoneal Carcinomatosis, Secondary (PID123 V2.0)Nab-Paclitaxel 100 / Bevacizumab 10, Ovarian ca (PID900 V1.0)Nab-Paclitaxel 80 / Relacorilant 150, Ovarian Carcinoma (PID3262 V1.0)Niraparib 300, ovarian carcinoma, maintenance (PID477 V1.1)Olaparib 300, Ovarian ca, maintenance (PID531 V2.0)Pembrolizumab 200 / Bevacizumab 15 / Cyclophosphamide 50, Ovarian ca (PID1109 V1.1)
